BYSI
BeyondSpring Inc.
There isn't enough reported data to score BYSI yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
BYSI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
BYSI's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BYSI PE Valuation
BYSI has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BYSI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect BYSI's losses to shrink, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
BYSI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.16 | -$0.02 |
| Q1 2026 | -$0.24 | -$0.11 |
| Q4 2025 | -$0.08 | +$0.26 |
| Q3 2025 | -$0.07 | +$0.34 |
| Q2 2025 | -$0.14 | +$0.27 |
| Q1 2025 | -$0.13 | +$0.34 |
| Q4 2024 | -$0.34 | +$0.20 |
| Q3 2024 | -$0.41 | +$0.21 |
BYSI is still losing money, but far less than before: $0.16 per share over the past year, against $2.04 at its worst in late 2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BYSI on earnings quality, reporting a profit while its opponent remains loss making.
BYSI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2024 | $500K | +14% |
| Q1 2024 | $500K | +14% |
| Q4 2023 | $438K | +30% |
| Q3 2023 | $438K | +30% |
| Q2 2023 | $437.5K | +29% |
| Q1 2023 | $437.5K | +29% |
| Q4 2022 | $337.5K | -0.1% |
| Q3 2022 | $337.5K | +0.1% |
BYSI's revenue has slid since its 2024 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2024 | -742% | +799 points |
| Q1 2024 | -742% | +799 points |
| Q4 2023 | -1099% | +1335 points |
| Q3 2023 | -1099% | +1335 points |
| Q2 2023 | -1541% | +1537 points |
| Q1 2023 | -1541% | +1537 points |
| Q4 2022 | -2434% | +670 points |
| Q3 2022 | -2434% | +3011 points |
BYSI's operating margin was −742% last quarter, up 799 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BYSI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
BYSI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.8M | +$2.1M |
| Q1 2026 | -$3.3M | +$971K |
| Q4 2025 | -$5.5M | -$5.5M |
| Q3 2025 | -$4.2M | -$4.2M |
| Q2 2025 | -$5.9M | -$5.9M |
| Q1 2025 | -$4.2M | -$4.2M |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
BYSI has burned cash in six of the last eight quarters: −$17M over the past year, against −$10M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BYSI on cash generation, producing positive trailing cash flow while its opponent burns cash.
BYSI Net Leverage
BYSI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
BYSI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.3 | Neutral |
| Stochastic | 21.8 | Neutral |
BYSI's weekly RSI is 36 (neutral) and its Stochastic is 22 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BYSI PE vs Healthcare Sector
BYSI has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BYSI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.63 | 4.8% below |
| 20 week MA | $0.86 | 30% below |
| 50 week MA | $1.33 | 55% below |
| 100 week MA | $1.58 | 62% below |
| 200 week MA | $1.61 | 63% below |
BYSI is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BYSI on trend strength, trading above more of its moving averages.
BYSI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.9 | $11.1 | -30% |
| 2021 | $11.1 | $4.92 | -55% |
| 2022 | $4.92 | $1.69 | -66% |
| 2023 | $1.69 | $0.90 | -47% |
| 2024 | $0.90 | $1.62 | +80% |
| 2025 | $1.62 | $1.84 | +14% |
| 2026 YTD | $1.84 | $0.60 | -67% |
BYSI has finished lower in four of the last six years. It's down 67% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BYSI on returns for 2026, with the stronger performance.